Eczema Trial, Recruiting (NCT07316465)

Eczema Trial, Recruiting NCT07316465 Sponsor: Universitair Ziekenhuis Brussel Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07316465 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your baby is planned to be born at the maternity ward of UZ Brussel hospital
Your baby is considered higher risk for developing eczema (atopic dermatitis) — meaning at least one parent or sibling has been diagnosed by a doctor with eczema, asthma, or hay fever (allergic rhinitis)
OR your baby is considered lower risk for developing eczema — meaning no parents or siblings have a history of eczema, asthma, or hay fever

Who may not be able to join:

Babies who are not born at the maternity ward of UZ Brussel
Parents who do not have a reasonable understanding of Dutch, French, or English
Babies who need to be admitted to the newborn intensive care unit after birth, were born before 34 weeks of pregnancy, or have medical complications after birth
Babies born with serious genetic conditions or birth defects
Families who will not be able to attend regular check-up visits over a 2-year period (for example, due to where they live or their work schedule)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jan Gutermuth, MD PhD, Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel (VUB)

Phone: +32 (0)2 477 4244

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07316465

Sponsor: Universitair Ziekenhuis Brussel

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: +32 (0)2 477 4244

More information: https://clinicaltrials.gov/study/NCT07316465

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your baby is planned to be born at the maternity ward of UZ Brussel hospital
Your baby is considered higher risk for developing eczema (atopic dermatitis) — meaning at least one parent or sibling has been diagnosed by a doctor with eczema, asthma, or hay fever (allergic rhinitis)
OR your baby is considered lower risk for developing eczema — meaning no parents or siblings have a history of eczema, asthma, or hay fever

Who may not be able to join:

Babies who are not born at the maternity ward of UZ Brussel
Parents who do not have a reasonable understanding of Dutch, French, or English
Babies who need to be admitted to the newborn intensive care unit after birth, were born before 34 weeks of pregnancy, or have medical complications after birth
Babies born with serious genetic conditions or birth defects
Families who will not be able to attend regular check-up visits over a 2-year period (for example, due to where they live or their work schedule)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Universitair Ziekenhuis Brussel

Registry

ClinicalTrials.gov

Start date

1 October 2023

Est. completion

31 December 2029

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Prevalence of IgE autoantibodies against skin epitopes in newborns

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov